FORM 10-QSB

                    U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


              [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended September 30, 2004
                            Commission File # 0-24875

                                BIOENVISION, INC.
        (Exact name of small business issuer as specified in its charter)



       Delaware                                             13-4025857
       --------                                               --------
      State or other jurisdiction                             IRS
     of incorporation or organization                         Employer ID No.

                 345 Park Avenue, 41st Floor, New York, NY 10154
                 -----------------------------------------------
                    (Address of principal executive offices)

(Issuer's Telephone Number)      (212) 750-6700
                                 --------------

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the Exchange  Act during the past twelve  months (or such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes ___X___ No _____


As of November 12, 2004,  there were  28,797,169  shares of the issuer's  common
stock, par value $.001 per share (the "Common Stock") outstanding.

Transitional Small Business Disclosure Format (Check One): YES [ ] No [X]





                                 C O N T E N T S






                                                                                                               Page
                                                                                                               ----
                                                                                                             
Condensed Consolidated Balance Sheets                                                                            1

Condensed Consolidated Statements of Operations                                                                  2

Condensed Consolidated Statements of Cash Flows                                                                  3

Notes to Condensed Consolidated Financial Statements                                                             4

Item 2.  Management's Discussion and Analysis of Financial Condition or Plan of Operation                       10

Item 4.  Controls and Procedures                                                                                15

Part II - Other Information                                                                                     16






                       Bioenvision, Inc. and Subsidiaries
                      CONDENSED CONSOLIDATED BALANCE SHEETS




                                                                                  September 30,                June 30,
                                                                                      2004                       2004
                                                                                  -----------                 -----------
                                 ASSETS                                            (unaudited)                
                                                                                                        
Current assets
    Cash and cash equivalents                                                     $17,662,989                 $18,875,675
    Restricted cash                                                                   290,000                     290,000
    Deferred costs                                                                    241,824                     241,824
    Accounts receivable                                                               860,284                   2,627,773
    Other assets                                                                      393,769                     253,311
                                                                                      -------                     -------

        Total current assets                                                       19,448,866                  22,288,583

    Property and equipment, net                                                        44,881                      47,857
    Intangible assets, net                                                         14,271,299                  14,563,660
    Goodwill                                                                        3,902,705                   3,902,705
    Security deposits                                                                  79,111                      79,111
    Deferred costs-long term                                                        3,591,015                   3,651,471
                                                                                    ---------                   ---------
        Total assets                                                              $41,337,877                 $44,533,387
                                                                                   ==========                  ==========

                   LIABILITIES AND STOCKHOLDERS' EQUITY

 Current liabilities
    Accounts payable                                                               $1,541,214                  $1,495,866
    Accrued expenses                                                                  869,572                   1,322,584
    Accrued dividends payable                                                          90,341                      90,141
    Deferred revenue                                                                  551,828                     551,828
                                                                                      -------                     -------

        Total current liabilities                                                   3,052,955                   3,460,419

Deferred revenue-long term                                                          7,771,640                   7,909,598
Deferred tax liability-non-current                                                  5,646,573                   5,780,799
                                                                                    ---------                   ---------

        Total liabilities                                                          16,471,168                  17,150,816
                                                                                   ----------                  ----------

 Stockholders' equity
    Preferred stock - $0.001 par value; 20,000,000 shares authorized;                   3,342                       3,342
      3,341,666 shares issued and outstanding at September 30, 2004 and
      June 30, 2004 (liquidation preference $10,024,998)
    Common stock - par value $0.001; 70,000,000 shares authorized;                     28,597                      28,316
      28,597,172 and 28,316,163 shares issued and outstanding at
      September 30, 2004 and June 30, 2004, respectively.
    Additional paid-in capital                                                     69,066,456                  68,517,702
    Deferred compensation                                                            (201,927)                   (223,990)
    Accumulated deficit                                                           (44,169,063)                (41,082,397)
    Accumulated other comprehensive income                                            139,304                     139,598
                                                                                      -------                     -------

         Stockholders' equity                                                      24,866,709                  27,382,571
                                                                                   ----------                  ----------

         Total liabilities and stockholders' equity                               $41,337,877                 $44,533,387
                                                                                  ===========                 ===========



The accompanying notes are an integral part of these financial statements.





                       Bioenvision, Inc. and Subsidiaries

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS





                                                                                 Three months ended
                                                                                    September 30,
                                                                                    -------------
                                                                             2004                     2003
                                                                             ----                     ----
                                                                         (unaudited)               (unaudited)
                                                                                          

    Licensing and royalty revenue                                         $363,182                  $54,041
    Research and development contract revenue                              722,146                  775,000
                                                                           -------                  -------

             Total revenue                                               1,085,328                  829,041

Costs and expenses
    Research and development                                             2,138,897                  803,900
    Selling, general and administrative                                  1,756,713                2,438,088
    (includes stock based compensation expense of $391,098
    and $1,284,646 for the three months ended September 30,
    2004 and 2003, respectively)

    Depreciation and amortization                                          339,706                  339,621
                                                                           -------                  -------

         Total costs and expenses                                        4,235,316                3,581,609
                                                                         ---------                ---------

Loss from operations                                                    (3,149,988)              (2,752,568)

Interest income (expense)
      Interest income                                                       55,437                   19,037
                                                                            ------                   ------


Net loss before income tax benefit                                      (3,094,551)              (2,733,531)

Income tax benefit                                                         134,226                  134,226
                                                                        ----------                  -------

Net loss                                                                (2,960,325)              (2,599,305)

Cumulative preferred stock dividend                                       (126,341)                (223,710)
                                                                          ---------                ---------

Net loss available to common stockholders                              $(3,086,666)             $(2,823,015)
                                                                        ===========              ===========


Basic and diluted net loss per share of common stock                        $(0.11)                  $(0.16)
                                                                             ======                   ======


Weighted average shares used in computing                               28,516,450               17,188,295
    basic and diluted net loss per share                                ==========               ==========


The accompanying notes are an integral part of these financial statements.


                                      -2-



                       Bioenvision, Inc. and Subsidiaries

                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS




                                                                                         Three months ended
                                                                                            September 30,
                                                                                --------------------------------------
                                                                                     2004                     2003
                                                                                -------------              -----------
                                                                                  (unaudited)              (unaudited)
                                                                                                    
 Cash flows from operating activities
     Net loss                                                                    $(2,960,325)             $(2,599,305)
     Adjustments to reconcile net loss to net
        cash used in operating activities
          Depreciation and amortization                                              339,706                  339,621
          Deferred tax benefit                                                      (134,226)                (134,226)
          Shares and warrants issued to non-employees                                566,943                  569,763
          Compensation costs - re-pricing of options                                (197,908)                 714,883
          Compensation costs-options issued to employees                              22,063                     -
          Changes in assets and liabilities
              Deferred costs                                                          60,456                    5,808
              Deferred revenue                                                      (137,958)                 (29,041)
              Accounts payable                                                        45,349                 (260,500)
              Other current assets                                                  (140,459)                (197,580)
              Other long term assets                                                    -                      81,692
              Accounts receivable                                                  1,767,489                        -
              Other accrued expenses and liabilities                                (453,012)                 352,977
                                                                                    ---------                 -------

                     Net cash used in operating activities                        (1,221,882)              (1,155,908)
                                                                                  -----------              -----------

 Cash flows from investing activities
     Purchase of intangible assets                                                   (42,115)                 (22,332)
     Capital expenditures                                                             (2,254)                     -
                                                                                  -----------              -----------

                     Net cash used in investing activities                           (44,368)                 (22,332)
                                                                                  -----------              -----------

 Cash flows from financing activities
     Proceeds from issuance of common stock                                             -                     262,500
     Proceeds from exercise of options, warrants and other convertible
     securities                                                                      180,000                     -
     Cash dividends paid                                                            (126,141)                    -
                                                                                  -----------              -----------

                Net cash provided by financing activities                             53,859                  262,500
                                                                                  -----------              -----------

 Effect of exchange rate on cash                                                        (294)                    -

 Net decrease in cash and cash equivalents                                        (1,212,685)                (915,740)

 Cash and cash equivalents, beginning of period                                   18,875,675                7,929,686
                                                                                  -----------              -----------

 Cash and cash equivalents, end of period                                        $17,662,989               $7,013,946
                                                                                 ===========               ==========

 Supplemental cash flow information

 Income taxes                                                                        $32,975                  $20,891


The accompanying notes are an integral part of these financial statements.


                                      -3-



                       BIOENVISION, INC. AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                               September 30, 2004

                                   (Unaudited)

NOTE A - Description of Business

Bioenvision,  Inc. (the "Company") is an emerging biopharmaceutical company that
develops and markets  drugs to treat  cancer.  The  Company's two lead drugs are
clofarabine and Modrenal(R), although the Company has several other products and
technologies  under  development.  As of November 8, 2004,  the Company  employs
eleven  full-time and four part-time  employees  based in New York, New York and
Edinburgh, Scotland.

The  Company's  primary  business  strategy  relates  to  its  two  lead  drugs,
clofarabine and  Modrenal(R).  With  clofarabine,  the Company's  strategy is to
complete drug development in Europe and obtain marketing  authorization from the
European regulatory  authorities to market and distribute  clofarabine in Europe
for the  treatment of pediatric  and adult acute  leukemias  (ALL and AML).  The
Company anticipates launching clofarabine in Europe in mid-2005,  subject to its
obtaining  from the  European  regulatory  authorities  the first  approval  for
clofarabine  which is expected to be for pediatric ALL and AML. The Company will
continue clinical trials in other indications with the intention of aggressively
seeking label  extensions  after  clofarabine's  first  approval,  including its
Pivotal  Phase II trial of  clofarabine  in adults with Acute  Myeloid  Leukemia
(AML) which  commenced in August 2004 and is ongoing.  Following  this strategy,
throughout the world, approximately two-thirds of the cancer patients dosed with
clofarabine to date fall outside of the pediatric acute leukemias.

Clofarabine  is a small  molecule and a purine  nucleoside  analogue,  which the
Company believes is effective in the treatment of leukemias,  based upon its own
clinical  studies  and  studies  conducted  by others on the  Company's  behalf.
Clofarabine  may also be an effective  agent to treat  patients with solid tumor
cancers,  based on preclinical  studies and Phase I clinical trials performed to
date.

Modrenal(R)  is a hormonal  agent  with a novel mode of action  that makes it an
effective  agent in  patients  with  advanced  breast  cancer who have  acquired
resistance to other hormonal  agents.  The Company  launched  Modrenal(R) in May
2003 in the United Kingdom, where it received regulatory approval for its use in
the  treatment  of  post-menopausal  breast  cancer.  In the  second  quarter of
calendar  year 2005,  the  Company  intends to apply for mutual  recognition  in
another  four  large  European  territories  in an effort to gain  approval  for
Modrenal(R) in each such territory.  The Company anticipates  receiving approval
in each such territory during calendar 2005, but such approval is subject to the
appropriate regulatory decisions.

With  Modrenal(R),  the  Company's  strategy  is to expand  sales in the  United
Kingdom  and apply for  mutual  recognition  to obtain  the right to market  and
distribute  Modrenal(R) in the major European markets.  The Company  anticipates
receiving mutual  recognition from major European  Community member states by Q3
of calendar 2005. The Company intends to further U.S. development of Modrenal(R)
in prostate and breast cancer indications, subject to the ongoing results of its
clinical trials it is currently conducting in the U.S. and Europe.

The  Company's  secondary  business  strategy  is to  continue  to  develop  its
portfolio of ancillary products and technologies.  The Company  anticipates that
revenues  derived from  clofarabine and  Modrenal(R) and milestone  payments and
royalties  from the  ancillary  products  will permit it to further  develop its
portfolio of ancillary products and technologies.

NOTE B - Interim Financial Statements

In the opinion of management, the accompanying unaudited condensed consolidated
financial statements contain all the adjustments necessary to present fairly the
consolidated financial position of the Company as of September 30, 2004 and the
consolidated results of operations and cash flows for the three months ended
September 30, 2004 and 2003.

The condensed consolidated balance sheet at June 30, 2004 has been derived from
the audited financial statements at that date, but does not include all the
information and footnotes required by accounting principles generally accepted
in the United States for complete financial statements. For further information,
refer to the audited consolidated financial statements and footnotes thereto
included in the Form 10-KSB filed by the Company for the year ended June 30,
2004.

The condensed consolidated results of operations for the three months ended
September 30, 2004 and 2003 are not necessarily indicative of the results to be
expected for any other interim period or for the full year.


                                      -4-



NOTE C - Stock Based Compensation

At September 30, 2004, the Company has stock based compensation plans which are
described more fully in the Company's annual report on Form 10-KSB for the year
ended June 30, 2004. As permitted by SFAS No. 123, "Accounting for Stock Based
Compensation," the Company accounts for stock based compensation arrangements in
accordance with provisions of Accounting Principles Board ("APB") Opinion No. 25
"Accounting for Stock Issued to Employees." Compensation expense for stock
options issued to employees is based on the difference on the date of grant,
between the fair value of the Company's stock and the exercise price of the
option. Under APB 25, no stock based employee compensation cost is reflected in
reported net loss, when options granted to employees have an exercise price
equal to the market value of the underlying common stock at the date of grant.
For the three months ended September 30, 2004, the Company recognized stock
based employee compensation income of $197,908, as a result of the March 31,
2003 re-pricing of 380,000 options granted to an employee pursuant to the terms
of his employment contract. For the three months ended September 30, 2004, the
Company recorded compensation expense of $22,063, as a result of options granted
to certain employees.

The Company accounts for equity instruments issued to non-employees in
accordance with the provisions of SFAS No. 123 and Emerging Issues Task Force
("EITF") No. 96-18, "Accounting for Equity Instruments That Are Issued to Other
Than Employees for Acquiring, or in Conjunction with Selling Goods or Services,"
as amended by EITF No. 00-27. Under EITF No. 96-18, where the fair value of the
equity instrument is more reliably measurable than the fair value of services
received, such services will be valued based on the fair value of the equity
instrument. The Company expects to continue applying the provisions of APB
Opinion No. 25 for equity issuances to employees.

The following table  illustrates the effect on net loss and loss per share as if
the fair value based  method had been  applied to all  outstanding  and unvested
awards in each period.




                                                                   Three months ended
                                                                      September 30
                                                                      ------------
                                                                2004               2003
                                                                ----               ----

                                                                      
Net loss available to common stockholders,                $(3,086,666)      $(2,823,015)
as reported                                               ------------      ------------
Add:  Stock based employee compensation                      (175,845)          714,883
 recognized under fair value based method for all
 awards

Deduct:  Total stock based employee compensation             (243,317)         (986,100)
recognized under fair value based method                     ---------         ---------
for all awards; net of related tax effects

Pro forma net loss                                        $(3,505,828)      $(3,094,232)
Loss per share                                            ============      ============
     Basic and diluted - as reported                      $   (0.11)        $   (0.16)

     Basic and diluted - pro forma                        $   (0.12)        $   (0.22)



The  fair  value of  options  at the date of grant  was  established  using  the
Black-Scholes model with the following assumptions:




                                                                   Three months ended
                                                                      September 30
                                                                      ------------
                                                                2004               2003
                                                                ----               ----

                                                                            
Expected life (years)                                            4                  4

Risk free interest rate                                        3.35%              3.00%

Expected volatility                                           80.00%              80.00%

Expected dividend yield                                        0.00                0.00


NOTE D - Net Loss Per Share

Basic net loss per share is computed using the weighted average number of common
shares  outstanding  during the periods.


                                      -5-



Diluted net loss per share is computed using the weighted average number of
common shares and potentially dilutive common shares outstanding during the
periods. Options and warrants to purchase 12,983,535 and 15,574,543 shares of
common stock have not been included in the calculation of net loss per share for
the three months ended September 30, 2004 and 2003, respectively, as their
effect would have been anti-dilutive.

NOTE E - License and Co-Development Agreements

                                   Clofarabine

The Company has a license from Southern Research Institute ("SRI"), Birmingham,
Alabama, to develop and market purine nucleoside analogs which, based on
third-party studies conducted to date, may be effective in the treatment of
leukemia, lymphoma and certain solid tumor cancers. The lead compound of these
purine-based nucleosides is known as clofarabine. Under the terms of the
agreement with SRI, the Company was granted the exclusive worldwide license,
excluding Japan and Southeast Asia, to make, use and sell products derived from
the technology for a term expiring on the date of expiration of the last patent
covered by the license (subject to earlier termination under certain
circumstances), and to utilize technical information related to the technology
to obtain patent and other proprietary rights to products developed by the
Company and by SRI from the technology. Initially, the Company is developing
clofarabine for the treatment of leukemia and lymphoma and studying its
potential role in treatment of solid tumors.

In August 2003, SRI granted the Company an irrevocable, exclusive option to
make, use and sell products derived from the technology in Japan and Southeast
Asia. The Company intends to convert the option to a license upon sourcing an
appropriate co-marketing partner to develop these rights in such territory.

To facilitate the development of clofarabine, the Company entered into a
co-development agreement with ILEX Oncology, Inc. ("ILEX") in March 2001 for the
development of clofarabine in cancer indications. Under the terms of the
co-development agreement, ILEX is required to pay all development costs in the
United States and Canada, and 50% of approved development costs worldwide
outside the U.S. and Canada (excluding Japan and Southeast Asia), in each case,
for the development of clofarabine in cancer indications. ILEX is responsible
for conducting all clinical trials and the filing and prosecution of
applications with applicable regulatory authorities in the United States and
Canada in cancer indications. The Company retains the right to handle those
matters in all territories outside the United States and Canada (excluding Japan
and Southeast Asia) and retains the right to handle these matters in the U.S.
and Canada in all non-cancer indications. The Company retained the exclusive
manufacturing and distribution rights in Europe and elsewhere worldwide, except
for the United States, Canada, Japan and Southeast Asia. Under the
co-development agreement, ILEX will have certain rights if it performs its
development obligations in accordance with that agreement. The Company would be
required to pay ILEX a royalty on sales outside the U.S., Canada, Japan and
Southeast Asia. In turn, ILEX, which would have U.S. and Canadian distribution
rights in cancer indications, would pay the Company a royalty on sales in the
U.S. and Canada. In addition, the Company received $7.5 million in milestone
payments from ILEX throughout the U.S. drug development program. Under the terms
of the co-development agreement, ILEX also pays royalties to Southern Research
Institute based on certain milestones. The Company also is obligated to pay
certain milestones and royalties to Southern Research Institute with respect to
clofarabine.

The Company received a nonrefundable upfront payment of $1.35 million when it
entered into the co-development agreement with ILEX and received an additional
$3.5 million in December 2003 when it converted ILEX's option to market
clofarabine in the U.S. into a sublicense. The Company received an additional
(i) $2 million in April 2004 upon ILEX's filing the New Drug Application for
clofarabine with FDA and (ii) $2 million from ILEX in September 2004 in
connection with the achievement of the NDA filing. The Company deferred the
upfront payment and recognized revenues ratably, on a straight-line basis over
the related service period, through December 2002. The Company has deferred the
milestone payments received to date and recognizes revenues ratably, on a
straight line basis over the related service period, through March 2021. For the
three months ended September 30, 2004 and 2003, the Company recognized revenues
of approximately $110,000, and $0, respectively, in connection with the
milestone payments received to date.

Deferred costs include royalty payments that became due and payable to SRI upon
the Company's execution of the co-development agreement with ILEX. The Company
defers all royalty payments made to SRI and recognizes these costs ratably, on a
straight-line basis concurrent with revenue that is recognized in connection
with research and development costs including approximately $55,000 and $0 for
the three months ended September 30, 2004 and 2003, respectively, related to
such charges.


                                      -6-



                                   Modrenal(R)

The Company holds an exclusive license, until the expiration of existing and new
patents related to Modrenal(R), to market Modrenal(R) in major international
territories, and an agreement with a United Kingdom company to co-develop
Modrenal(R) for other therapeutic indications. Management believes that
Modrenal(R) currently is manufactured by third-party contractors in accordance
with good manufacturing practices. The Company has no plans to establish its own
manufacturing facility for Modrenal(R), but will continue to use third-party
contractors.

The Company received a nonrefundable upfront payment of $1.25 million when it
entered into the License and Sublicense Agreement with Dechra Pharmaceuticals in
May 2003. The Company deferred the upfront payment and recognizes revenues
ratably, on a straight-line basis over the related service period, through May
2014. The Company recognized revenues of approximately $28,000 and $29,000 in
connection with the upfront payment from Dechra for the three months ended
September 30, 2004 and 2003, respectively.

Deferred costs include royalty payments that became due and payable to Stegram
Pharmaceuticals Ltd. upon the Company's execution of the License and Sub-License
Agreement with Dechra in May 2003. The Company defers all royalty payments made
to Stegram and recognizes these costs ratably, on a straight-line basis
concurrent with revenue that is recognized in connection with the Dechra
agreement. Research and Development costs include approximately $5,700 and
$5,800 for the three months ended September 30, 2004 and 2003, respectively.

Anti-Estrogen Prostate. We received Institutional Review Board approval from the
Dana Faber Cancer Institute for a Phase II study of trilostane for the treatment
of androgen independent prostate cancer. The study is being conducted by The
Dana Faber Cancer Institute and commenced in July 2004.

Operational Developments

In June 2003, the Company entered into a supply agreement with Ferro-Pfanstiehl
Laboratories ("Ferro"), pursuant to which Ferro has agreed to manufacture and
supply 100% of Bioenvision's global requirements for clofarabine-API. Subject to
certain circumstances, this agreement will expire on the fifth anniversary date
of the first regulatory approval of clofarabine drug product.

In June 2003, the Company entered into a development agreement with Ferro,
pursuant to which Ferro agreed to perform certain development activities to
scale up, develop, finalize, and supply CTM and GMP supplier qualifications of
the API- clofarabine. Subject to certain circumstances, this agreement expires
upon the completion of the development program. The development agreement is
milestone-based and payments are to be paid upon completion of each milestone.
If Ferro has not completed the development agreement by December 2007, the
development agreement will automatically terminate without further action by
either party.

In May 2003, we entered into a sub-license agreement with Dechra, pursuant to
which Dechra has been granted a sub-license for all of Bioenvision's rights and
entitlements to market and distribute Modrenal(R) in the United States and
Canada solely in connection with animal health applications. Subject to certain
circumstances, this agreement expires upon expiration of the last patent related
to Modrenal(R) or the completion of the last royalty set forth in the agreement.
Through September 30, 2004, we have recognized revenue and costs related to this
agreement of approximately $155,000 and $31,000 respectively. The Company
received an upfront non-refundable payment of $1.25 million upon execution of
this agreement and may receive up to an additional $3.75 million upon the
achievement by Dechra of certain milestones set forth in the agreement.

In May 2003, we entered into a master services agreement with
Penn-Pharmaceutical Services Limited ("Penn"), pursuant to which Penn has agreed
to label, package and distribute clofarabine on our behalf and at our request.
The services to be performed by Penn also include regulatory support and the
manufacture, quality control, packaging and distribution of proprietary
medicinal products including clinical trials supplies and samples. Subject to
certain circumstances, the term of this agreement is twelve months and renews
for subsequent twelve month periods unless either party tenders notice of
termination upon no less than three month prior written notice.

In April 2003, we entered into an exclusive license agreement with CLL-Pharma
("CLL"), pursuant to which CLL has agreed to perform certain development works
and studies to create a new formulation of Modrenal(R). CLL intends to use its
proprietary MIDDS.-patented technology to perform this service on behalf of the
Company. This new formulation, once in hand, will allow the Company to apply for
necessary authorization, as required by applicable European health authorities,
to sell Modrenal(R) throughout Europe. Through September 30, 2004, the Company
paid an advance of $175,000 related to development services provided by CLL over
an eighteen month period, which advance was initially recorded as a prepaid
development cost by the Company.


                                      -7-



NOTE F - Equity Transactions

In June 2002,  the  Company  granted  options  to an  officer of the  Company to
purchase 380,000 shares of common stock at an exercise price of $1.95 per share,
which  equaled  the stock  price on the date of  grant.  Of this  amount  50,000
options vested on June 28, 2002 and the remaining  330,000  options vest ratably
over a  three-year  period on each  anniversary  date.  On March 31,  2003,  the
Company  entered into an Employment  Agreement with such officer of the Company,
pursuant to which, among other things, the exercise price for all of the 380,000
options were changed to $0.735 per share,  which equaled the stock price on that
date.  In  addition,  the Company  issued an  additional  120,000  options at an
exercise  price of $.735 per share  which vest  immediately.  As a result of the
repricing  of all  of the  380,000  options,  the  Company  will  remeasure  the
intrinsic  value of these options at the end of each  reporting  period and will
record a charge for compensation expense to the extent the vested portion of the
options are in the money.  For the three  months  ended  September  30, 2004 and
2003,  the Company  recognized  stock based income  (expense)  of  approximately
$198,000 and $(715,000), respectively, due the re-pricing of said options.

The Company recorded  compensation expense of $22,063 for the three months ended
September 30, 2004 as a result of 505,000 options issued to certain employees on
January 20, 2004.

On January 20, 2004, the Company granted 25,000 options to Dr. Michael  Kauffman
for serving as a member of the Board of Directors, at an exercise price of $4.55
per share which vest ratably on the first and second  anniversaries of the grant
date.  The  Company  recognized  $11,805 as a  consulting  expense for the three
months ended September 30, 2004 relating to said options.

On June 22, 2004, the Company  entered into a consulting  agreement  pursuant to
which the consultant will provide certain investor  relations services on behalf
of the Company.  In connection  therewith,  the Company issued a warrant to said
consultant  pursuant to which he has the right to purchase  50,000 shares of the
Company's  common  stock at a price of $8.25 per share  upon the  completion  of
certain  milestones,  as set  forth  in such  agreement.  The  Company  recorded
$218,430 as  consulting  expense for the three months ended  September  30, 2004
relating to said warrants.

On August 4, 2004,  the  Company  issued a warrant to a  consultant  pursuant to
which said  consultant has the right to purchase  40,000 shares of the Company's
common  stock  at a price  of $7.22  per  share  upon  satisfaction  of  certain
milestones included in the warrant.  The Company recorded $155,396 as consulting
expense for the three months ended September 30, 2004 relating to said warrants.

 On August 9, 2004, the Company issued two warrants to a consultant  pursuant to
which said  consultant has the right to purchase  45,000 shares of the Company's
common  stock at a price of $6.10 per share.  The Company  recorded  $181,313 as
consulting  expense for the three months ended  September  30, 2004  relating to
said warrants.

During the three months ended September 30, 2004, certain warrant holders of the
Company exercised their warrants to acquire 214,277shares of the Company's
common stock. The Company received proceeds of approximately $117,500 during the
three months ended September 30, 2004 from the exercise of warrants.

During the three month period ended September 30, 2004, certain holders of
options to purchase an aggregate of 66,732 shares of the Company's common stock
were exercised. The Company received proceeds of $62,500 during the three months
ended September 30, 2004 from the exercise of options.

NOTE G - Related Party Transactions

In May 2002, we completed a private placement pursuant to which we issued an
aggregate of 5,916,666 shares of Series A convertible participating preferred
stock for $3.00 per share and warrants to purchase an aggregate of 5,916,666
shares of common stock and in March of 2004 we consummated a private placement
pursuant to which we raised $12.8 million with a second closing in May 2004 in
which we raised an additional $3.5 million. An affiliate of SCO Capital Partners
LLC, one of our stockholders, served as financial advisor to the Company in
connection with these financings and earned a placement fee of approximately
$1.2 million in connection with May 2002 private placement and a placement fee
of $1.1 million and warrants to purchase 260,291 shares of common stock for
$6.25 per share for the March and May 2004 financings.

NOTE H - New Accounting Pronouncements

In May 2003, the Emerging Issues Task Force ("EITF") reached a consensus on EITF
Issue No.  00-21,  "Revenue  Arrangements  with  Multiple  Deliverables"  ("EITF
00-21").  EITF 00-21  provides  guidance on how to determine when an arrangement
that involves multiple  revenue-generating  activities or deliverables should be
divided into separate units of


                                      -8-



accounting for revenue recognition  purposes,  and if this division is required,
how the arrangement  consideration  should be allocated among the separate units
of  accounting.   The  guidance  in  the  consensus  is  effective  for  revenue
arrangements  entered  into in  quarters  beginning  after  June 15,  2003.  The
adoption  of EITF  00-21 did not  impact the  Company's  consolidated  financial
position  or results of  operations,  but could  affect the timing or pattern of
revenue recognition for future collaborative research and/or license agreements.

NOTE I -  Litigation

 On April 1, 2003, RLB Capital,  Inc.  filed a complaint  against the Company in
the Supreme Court of the State of New York (Index No. 601058/03).  The Complaint
alleged a breach of contract by the Company and  demanded  judgment  against the
Company for  $112,500  and warrants to acquire  75,000  shares of the  Company's
common stock. The Company submitted its Verified Answer on June 25, 2003 and, in
pertinent part,  denied RLB's  allegations and asserted  counterclaims  based on
negligence.  In September 2003, the Company filed a motion for summary  judgment
and RLB filed its  response  on October 27,  2003.  On November  12,  2003,  the
Supreme  Court  granted the motion for summary  judgment and the  complaint  was
dismissed.  In March 2004, the complaint and two  counterclaims  asserted by the
Company were dismissed with prejudice.

 On December 19, 2003, the Company filed a complaint  against Dr. Deidre Tessman
and Tessman  Technology Ltd. (the "Tessman  Defendants") in the Supreme Court of
the State of New York,  County of New York  (Index  No.  03-603984).  An amended
complaint  alleges,  among other  things,  breach of contract and  negligence by
Tessman and Tessman  Technology and demands judgment against Tessman and Tessman
Technology in an amount to be determined  by the Court.  The Tessman  Defendants
removed the case to federal court, then remanded it to state court and served an
answer with several purported counterclaims.  The Company denies the allegations
in the  counterclaims  and  intends  to pursue its claims  against  the  Tessman
Defendants vigorously.


                                      -9-



                       BIOENVISION, INC. AND SUBSIDIARIES

ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL  CONDITION OR PLAN OF
OPERATION

Except for historical information contained herein, this quarterly report on
Form 10-QSB contains forward-looking statements within the meaning of the
Section 21E of the Securities and Exchange Act of 1934, as amended, which
involve certain risks and uncertainties. Forward-looking statements are included
with respect to, among other things, the Company's current business plan an "
Managements Discussion and Analysis of Results of Operations". These
forward-looking statements are identified by their use of such terms and phrases
as "intends," "intend," "intended," "goal," "estimate," "estimates," "expects,"
"expect," "expected," "project," "projected," "projections," "plans,"
"anticipates," "anticipated," "should," "designed to," "foreseeable future,"
"believe," "believes" and "scheduled" and similar expressions. The Company's
actual results or outcomes may differ materially from those anticipated. Readers
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date the statement was made. The Company undertakes
no obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

The  following  discussion  and analysis of  significant  factors  affecting the
Company's operating results, liquidity and capital resources and should be read
in conjunction with the accompanying financial statements and related notes.

Overview

We are an emerging  biopharmaceutical company that develops and markets drugs to
treat cancer.  Our two lead drugs are clofarabine and  Modrenal(R),  although we
have several other products and technologies under  development.  As of November
8, 2004, we employ eleven  full-time and four part-time  employees  based in New
York, New York and Edinburgh, Scotland.

Our primary  business  strategy  relates to our two lead drugs,  clofarabine and
Modrenal(R).  With clofarabine,  our strategy is to complete drug development in
Europe  and  obtain  marketing   authorization  from  the  European   regulatory
authorities to market and distribute  clofarabine in Europe for the treatment of
pediatric  and adult acute  leukemias  (ALL and AML).  We  anticipate  launching
clofarabine  in Europe in mid-2005,  subject to our obtaining  from the European
regulatory  authorities the first approval for clofarabine  which is expected to
be for  pediatric  ALL and  AML.  We will  continue  clinical  trials  in  other
indications  with the intention of aggressively  seeking label  extensions after
clofarabine's   first  approval,   including  our  Pivotal  Phase  II  trial  of
clofarabine  in adults with Acute  Myeloid  Leukemia  (AML) which  commenced  in
August 2004 and is  ongoing.  Following  this  strategy,  throughout  the world,
approximately  two-thirds of the cancer patients dosed with  clofarabine to date
fall outside of the pediatric acute leukemias.

With  Modrenal(R),  our  strategy is to expand  sales in the United  Kingdom and
apply for  mutual  recognition  to obtain  the  right to market  and  distribute
Modrenal(R)  in the major  European  markets.  We  anticipate  receiving  mutual
recognition from major European  Community member states by Q3 of calendar 2005.
We intend to further  U.S.  development  of  Modrenal(R)  in prostate and breast
cancer indications, subject to the ongoing results of our clinical trials we are
currently conducting in the U.S. and Europe.

Our  secondary  business  strategy is to continue  to develop our  portfolio  of
ancillary  products and  technologies.  We anticipate that revenues derived from
clofarabine  and  Modrenal(R)  and  milestone  payments and  royalties  from the
ancillary  products will permit us to further develop our portfolio of ancillary
products and technologies.

Over the next 12 months,  we intend to continue our internal  growth strategy to
provide the necessary regulatory, sales and marketing capabilities which will be
required  to pursue  the  expanded  development  programs  for  clofarabine  and
Modrenal(R) described above.

Clofarabine  is a small  molecule  and a purine  nucleoside  analogue,  which we
believe is effective in the treatment of leukemias,  based upon our own clinical
studies and studies  conducted by others on our behalf.  Clofarabine may also be
an  effective  agent  to treat  patients  with  solid  tumor  cancers,  based on
preclinical studies and Phase I clinical trials performed to date.

In July 2004, we filed for approval of  clofarabine  in Europe to treat children
with  pediatric  acute  leukemia  (ALL and AML).  Further,  we are  conducting a
Pivotal Phase II clinical  trial of  clofarabine,  as first line therapy for the
treatment of adults with


                                      -10-



Acute Myeloid Leukemia (AML). Also in Europe, at our direction,  an Investigator
Sponsored  Trial of  clofarabine  as first-line  therapy for adults with AML was
completed  ahead of schedule  and an interim  analysis  indicates a 64% complete
response rate observed in this patient population.

In the U.S., ILEX Oncology,  Inc., our  sub-licensor of U.S. and Canadian cancer
marketing  rights,  filed a New  Drug  Application  ("NDA")  in  March  2004 for
approval of clofarabine to treat children with acute leukemias (ALL or AML). The
NDA was based upon results of two Pivotal Phase II clinical trials  completed by
ILEX prior to the NDA filing. In connection with the NDA, the United States Food
and Drug  Administration  (the "FDA") has set a  Prescription  Drug User Fee Act
("PDUFA") response date at December 30, 2004. A PDUFA date is the is the date by
which the FDA is expected to review and act upon an NDA submission.  Clofarabine
will be  reviewed  by the FDA  Oncologic  Drug  Advisory  Committee  ("ODAC") on
December 1, 2004.

In January, 2002, the European orphan drug application for use of clofarabine to
treat acute leukemia in adults was approved.  Orphan Drug  Designation  provides
the Company with ten years of market exclusivity in Europe for clofarabine, upon
grant of marketing  authorization.  The drug has also been  granted  orphan drug
status and "fast track"  treatment by the FDA.  Further,  in July 2004,  the FDA
granted six months of extended market  exclusivity to clofarabine under the Best
Pharmaceuticals for Children Act.

In August 2003, we obtained the exclusive,  irrevocable  option to sell,  market
and  distribute  clofarabine  in Japan and  Southeast  Asia from the inventor of
clofarabine.  These  rights were not  previously  granted by  Southern  Research
Institute and fall outside the scope of the Company's then current licensing and
development  contracts with respect to  clofarabine.  We originally  obtained an
exclusive  license  from  Southern  Research   Institute  to  sell,  market  and
distribute  clofarabine  throughout  the world,  except for Japan and  Southeast
Asia, for all human applications,  pursuant to a co-development agreement, dated
August 31, 1998, between the Company and Southern Research  Institute.  On March
12,  2001,  we  granted  an  exclusive  option to sell,  market  and  distribute
clofarabine  in the U.S. and Canada to ILEX Oncology,  Inc. We converted  ILEX's
option to an exclusive sublicense on December 30, 2003.  Accordingly,  we do not
possess  the  rights to sell,  market  and  distribute  clofarabine  for  cancer
indications in the U.S.

Modrenal(R)  is a hormonal  agent  with a novel mode of action  that makes it an
effective  agent in  patients  with  advanced  breast  cancer who have  acquired
resistance to other hormonal agents. We launched  Modrenal(R) in May 2003 in the
United Kingdom,  where we have received  regulatory  approval for its use in the
treatment of  post-menopausal  breast cancer.  In the second quarter of calendar
2005, we intend to apply for mutual  recognition  in another four large European
territories  in an  effort  to  gain  approval  for  Modrenal(R)  in  each  such
territory.  We  anticipate  receiving  approval  in each such  territory  during
calendar  2005,  but such  approval  is  subject to the  appropriate  regulatory
decisions.

In the U.S., we filed an IND to conduct Modrenal(R) clinical trials for prostate
cancer in February 2004 and commenced  enrolling patients in this clinical trial
in July 2004.  Further, we intend to seek regulatory approval for Modrenal(R) in
the United States as salvage  therapy for  hormone-sensitive  breast cancer upon
completion of additional clinical studies.

We originally obtained an exclusive license from Stegram Pharmaceuticals Ltd. to
sell, market and distribute  Modrenal(R)  throughout the world, except for South
Africa,   for  all  human  and  animal  health   applications,   pursuant  to  a
co-development agreement dated July 15, 1998.

Company Status

We have made significant  progress in developing our product  portfolio over the
past twelve  months,  and have  multiple  products in clinical  trials.  We have
incurred losses during this emerging stage. Our management believes that we have
the opportunity to become a leading  oncology-focused  pharmaceutical company in
the next four years if we successfully bring clofarabine to market and if mutual
recognition  is granted  for  Modrenal(R)  in the  largest  European  commercial
markets.

We anticipate  that revenues  derived from our two lead drugs,  clofarabine  and
Modrenal(R)  will permit us to further  develop the other products  currently in
our product  pipeline.  We  anticipate  the launch of  clofarabine  in Europe by
mid-2005  and  further  anticipate  reaching   profitability  within  12  months
following the marketing launch for clofarabine in Europe.

We commenced marketing one of our lead products,  Modrenal(R),  in June 2003 and
have commenced  building out our internal  infrastructure of sales and marketing
professionals  to sell Modrenal(R) and to conduct  pre-marketing  activities for
clofarabine  in Europe.  Management  believes  it can create  synergies  through
internal  growth by developing a sales and marketing  presence  which will be in
position to sell both lead drugs at lead European  cancer centers across a broad
range of cancer indications.


                                      -11-



Further,  we intend to continue  developing our existing  platform  technologies
with a primary  business  focus on drugs to treat  cancer,  and  commercializing
products  derived  from such  technologies.  As a result of the  acquisition  of
Pathagon,  Inc. in February 2002, we have several  anti-infective  technologies.
These include the OLIGON(R)  technology,  an advanced  biomaterial that has been
approved for certain  indications by the FDA in the U.S., and is being sold by a
product co-development  partner, and the use of thiazine dyes, such as methylene
blue,  which  are  used  for in  vitro  and in vivo  inactivation  of  pathogens
(viruses,  bacteria and fungus) in  biological  fluids.  It is not the Company's
strategy to sell devices or to expand into the anti-infective market per se, but
the technology obtained in the Pathagon acquisition has specific application for
support of the cancer patient and oncology  treatment.  We have had  discussions
with potential  product  co-development  partners from time to time, and plan to
continue to explore the  possibilities for  co-development  and sub-licensing in
order to implement our development  plans. In addition,  we believe that some of
our products may have applications in treating  non-cancer  conditions in humans
and in animals.  Those  conditions are outside our core business focus and we do
not  presently  intend to  devote a  substantial  portion  of our  resources  to
addressing  those  conditions.  In May  2003,  we  entered  into a  License  and
Sub-License Agreement with Dechra Pharmaceuticals,  plc ("Dechra"),  pursuant to
which we  sub-licensed  the  marketing  and  development  rights  to  vetoryl(R)
trilostane,  solely with respect to animal  health  applications,  in the United
States and Canada, to Dechra.  We received $1.25 million in cash,  together with
future  milestone and royalty  payments which are contingent upon the occurrence
of certain events. We intend to continue to try and capitalize on these types of
opportunities as they arise.

You  should  consider  the  likelihood  of  our  future  success  to  be  highly
speculative in light of our limited  operating  history,  as well as the limited
resources, problems, expenses, risks and complications frequently encountered by
similarly  situated  companies.  To address  these risks,  we must,  among other
things:

o    satisfy our future capital requirements for the implementation of our
     business plan;

o    commercialize our existing products;

o    complete development of products presently in our pipeline and obtain
     necessary regulatory approvals for use;

o    implement and successfully execute our business and marketing strategy to
     commercialize products;

o    establish and maintain our client base;

o    continue to develop new products and upgrade our existing products;

o    respond to industry and competitive developments; and

o    attract, retain, and motivate qualified personnel.

We may not be successful in addressing  these risks. If we were unable to do so,
our business  prospects,  financial condition and results of operations would be
materially adversely affected.  The likelihood of our success must be considered
in  light  of  the  development  cycles  of  new  pharmaceutical   products  and
technologies and the competitive and regulatory environment in which we operate.

Results of Operations

We have acquired development and marketing rights to a portfolio of six platform
technologies from which a range of products have been derived and additional
products may be developed in the future. Although we intend to commence
marketing our lead product, Modrenal(R), and to continue developing our existing
platform technologies and commercializing products derived from such
technologies, a key element of our business strategy is to continue to develop
new technologies and products that we believe offer unique market opportunities
and/or complement our existing product lines. Once a product or technology has
been launched into the market for a particular disease indication, we plan to
work with numerous collaborators, both pharmaceutical and clinical, in the
oncology community to extend the permitted uses of the product to other
indications. In order to market our products effectively, we intend to develop
marketing alliances with strategic partners and may co-promote and/or co-market
in certain territories.

The Company recorded revenues for the three months ended September 30, 2004 and
2003 of approximately $1,085,000 and $830,000, respectively, representing an
increase of $255,000. Of the revenues recorded for the three months ended
September 30, 2004, approximately $830,000 was recognized from ILEX, pursuant to
the Co-Development Agreement, and approximately $189,000 was recognized from
Stegram Pharmaceuticals under the Stegram Co-Development Agreement.



                                      -12-



Research and development costs for the three months ended September 30, 2004 and
2003 were approximately $2,139,000 and $804,000,  respectively,  representing an
increase of $1,335,000.

Our research and development  costs include costs  associated with six projects,
four of which, the Company devotes  significant  time and resource.  Clofarabine
research and development costs for the three months ended September 30, 2004 and
2003 were approximately $1,880,000 and $436,000,  respectively,  representing an
increase of  approximately  $1,444,000.  The increase  primarily  reflects costs
which are  associated  with our increased  development  activities  and clinical
trials being  conducted in Europe and costs  associated with our filing a Common
Technical  Document with EMEA for approval of  clofarabine  for the treatment of
pediatric acute leukemias, which filing occurred in July 2004.

Modrenal(R)  research and development costs for the three months ended September
30,  2004 and 2003  were  approximately  $250,000  and  $283,000,  respectively,
representing  a  decrease  of  $33,000.  The  decrease  primarily  reflects  our
increased  focus on  clofarabine  during this period,  including  the filing for
approval of clofarabine in Europe which occurred in July 2004.

Gossypol research and development costs for the three months ended September 30,
2004 and 2003 were approximately $8,000 and $64,000, respectively, representing
a decrease of $56,000. The decrease primarily reflects our increased focus on
clofarabine during this period, including the filing for approval of clofarabine
in Europe which occurred in July 2004.

The clinical trials and development strategy for the clofarabine and Modrenal(R)
projects,  in each case, is anticipated to cost several million dollars and will
continue for several  years based on the number of clinical  indications  within
which we plan to develop these drugs. Currently,  management cannot estimate the
timing or costs  associated  with these projects  because many of the variables,
such as interaction  with  regulatory  authorities and response rates in various
clinical  trials,  are not  predictable.  Total  costs  to date  for four of our
projects is as follows: (i) clofarabine research and development costs have been
approximately  $7,500,000;  (ii) Modrenal(R) research and development costs have
been  approximately  $4,600,000;  (iii) Gossypol  research and development costs
have been approximately $308,000; and (iv) Gene Therapy research and development
costs have been approximately  $450,000.  Our other two research and development
projects involve our two ancillary  technologies;  OLIGON and Methylene Blue. We
do not currently  devote any significant time or resources to these research and
development  projects,  but  we  intend  to  do so  if  and  to  the  extent  we
successfully commercialize our lead drugs, clofarabine and Modrenal(R), over the
next two years.

Selling, general and administrative expenses for the three months ended
September 30, 2004 and 2003 were approximately $1,756,000 and $2,438,000,
respectively, representing a decrease of $681,000. The decrease primarily
relates to stock based compensation recorded during the period resulting from
the repricing of the options issued to an officer of the Company.

Depreciation and amortization expense for the three months ended September 30,
2004 and 2003 were $340,000 and $340,000, respectively.

Liquidity and Capital Resources

We anticipate that we may continue to incur significant operating losses for the
foreseeable future. There can be no assurance as to whether or when we will
generate material revenues or achieve profitable operations.

The Company received a nonrefundable upfront payment of $1.35 million when it
entered into the co-development agreement with ILEX and received an additional
$3.5 million in December 2003 when it converted ILEX's option to market
clofarabine in the U.S. into a sublicense. The Company received an additional
(i) $2 million in April 2004 upon ILEX's filing the New Drug Application for
clofarabine with FDA and (ii) $2 million from ILEX in September 2004 in
connection with ILEX having completed such NDA filing. The Company deferred the
upfront payment and recognized revenues ratably, on a straight-line basis over
the related royalty period, through December 2002. The Company has deferred the
milestone payments received to date and recognizes revenues ratably, on a
straight line basis over the related service period, through March 2021. For the
three months ended September 30, 2004, the Company recognized revenues of
approximately $111,000 in connection with the milestone payments received to
date.

Deferred costs included royalty payments that became due and payable to SRI upon
the Company's execution of the co-development agreement with ILEX. The Company
defers all royalty payments made to SRI and recognizes these costs ratably, on a
straight-line basis, concurrent with revenue that is recognized in connection
with the ILEX agreement. Research and Development costs include approximately
$55,000 for the three months ended September 30, 2004 related to such charges.


                                      -13-



The Company received a nonrefundable upfront payment of $1.25 million when it
entered into the License and Sublicense Agreement with Dechra Pharmaceuticals in
May 2003. The Company deferred the upfront payment and recognizes revenues
ratably, on a straight-line basis over the related royalty period, through May
2014. The Company recognized revenues of approximately $28,000 and $29,000 in
connection with the upfront payment from Dechra for the three months ended
September 30, 2004 and 2003, respectively.

Deferred costs include royalty payments that became due and payable to Stegram
Pharmaceuticals Ltd. upon the Company's execution of the License and Sub-License
Agreement with Dechra in May 2003. The Company defers all royalty payments made
to Stegram and recognizes these costs ratably, on a straight-line basis
concurrent with revenue that is recognized in connection with the Dechra
agreement. Research and Development costs include approximately $5,700 and
$5,800 for the three months ended September 30, 2004 and 2003, respectively.

On May 7, 2002 we authorized the issuance and sale of up to 5,920,000 shares of
Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock
may be converted into shares of common stock at an initial conversion price of
$1.50 per share of common stock, subject to adjustment for stock splits, stock
dividends, mergers, issuances of cheap stock and other similar transactions.
Holders of Series A Convertible Preferred Stock also received, in respect of
each share of Series A Convertible Preferred Stock purchased in a private
placement which took place in May 2002, one warrant to purchase one share of our
common stock at an initial exercise price of $2.00 subject to adjustment.

Through May 16, 2002 we have sold an aggregate of 5,916,666 shares of Series A
Convertible Preferred Stock in the May 2002 private placement for $3.00 per
share and warrants to purchase an aggregate of 5,916,666 shares of common stock,
resulting in aggregate gross proceeds of approximately $17,750,000. A portion of
the proceeds were used to repay in full the Jano Holdings and SCO Capital
obligations upon which such facilities were terminated as well as to repay fees
amounting to $1,610,000 related to the transaction.

On March 22, 2004, we consummated a private placement transaction, pursuant to
which we raised $12.8 million and issued 2,044,514 shares of our common stock
and warrants to purchase an additional 408,903 shares of our common stock at a
conversion price of $7.50 per share. We recorded proceeds of $11,792,801 net of
all legal, professional and financing fees incurred in connection with the
offering. We consummated a second closing for this financing on May 13, 2004 in
order to comply with certain contractual obligations to our holders of Series A
Convertible Preferred Stock which hold preemptive rights for equity offerings.
We raised an additional $3.2 million (net of all legal, professional and
financial services incurred) from the second closing and issued an additional
558,384 shares of our common stock and warrants to purchase 111,677 shares of
our common stock at a conversion price of $7.50 per share.

On September 30, 2004, we have cash and cash equivalents of approximately
$17,663,000 and working capital of $16,396,000 which management believes will be
sufficient to continue currently planned operations over the next 12 months. We
can not ensure additional funds will not be raised during the next twelve months
because of the significant scale up of our operating activities, including
clofarabine development, the potential launch of clofarabine, and the launch of
Modrenal(R). However, if required or desirable, there can be no assurance that
suitable debt or equity financing will be available for the Company. Further,
although we do not currently plan to acquire or obtain licenses for new
technologies, if any such opportunity arises and we deem it to be in our
interests to pursue such an opportunity, it is possible that additional
financing would be required for such a purpose.

We anticipate that we may continue to incur significant operating losses for the
foreseeable future. There can be no assurance as to whether or where we will
generate material revenues or achieve profitable operations.

         The Company has the following commitments as of September 30, 2004:




                                            Payments Due in
---------------------------------------------------------------------------------------------------
                                     Total          2005          2006        2007     Thereafter
---------------------------------------------------------------------------------------------------
                                                                            
Employee Contracts                      824,539         662,039     162,500          -           -
---------------------------------------------------------------------------------------------------
Occupancy Lease and Automobiles       1,547,435         259,105     332,043    323,855     632,432
---------------------------------------------------------------------------------------------------
Total                                 2,371,974         921,144     494,543    323,855     632,432
---------------------------------------------------------------------------------------------------


The Company leased 3,229 square feet under a lease that expires on September 30,
2005. This lease was terminated on October 31, 2004.


                                      -14-



Subsequent Events

On October 25, 2004, the Company filed a $90 million shelf registration
statement with the Securities and Exchange Commission. The Company announced
that, if consummated, the proceeds from the offering would be used for the
marketing launch of clofarabine in Europe and expanding the Company's existing
sales and marketing infrastructure to accommodate European sales of both
clofarabine and Modrenal(R).

On October 20, 2004, the Company appointed Dr. Achim Mueller to serve as
European Marketing Manager and appointed Mr. Robert Bradbury to serve as U.K.
Sales Manager. Further, in November 2004, the Company commenced development of
its sales infrastructure by appointing four U.K. sales representatives. The
Company intends to hire additional sales representatives in the U.K. and in
other European countries over the course of the next 12 months.

In October, 2004, the Company executed a Sublease Agreement pursuant to which we
sublease 5,549 square feet of commercial space at 345 Park Avenue, 41st Floor,
New York, NY 10154, which is the new location of the Company's principal
executive offices. Subject to the terms and conditions of the Sublease
Agreement, the lease expires on December 31, 2009.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our principal  executive officer and principal  financial officer have evaluated
the  effectiveness  of the design and operation of our  disclosure  controls and
procedures  (as defined in Rules  13a-15(e) and 15d-15(e)  under the  Securities
Exchange  Act of 1934,  as amended) as of the end of the period  covered by this
quarterly  report  on Form  10-QSB.  Based  on this  evaluation,  our  principal
executive   officer  and  principal   financial  officer  concluded  that  these
disclosure controls and procedures are effective and designed to ensure that the
information required to be disclosed in our reports filed or submitted under the
Securities Exchange Act of 1934, as amended, is recorded, processed,  summarized
and reported within the requisite time periods.

In connection with its review of the Company's consolidated financial statements
for and as of the three month period ended March 31,  2004,  Grant  Thornton LLP
("Grant Thornton"),  the Company's  independent  accountants,  advised the Audit
Committee and management of certain  significant  internal control  deficiencies
that they considered to be, in the aggregate,  a material  weakness,  including,
inadequate staffing and supervision  leading to the untimely  identification and
resolution of certain  accounting  matters;  failure to perform timely  reviews,
substantiation  and evaluation of certain general ledger account balances;  lack
of  procedures  or  expertise  needed to prepare all required  disclosures;  and
evidence that  employees lack the  qualifications  and training to fulfill their
assigned  functions.   Grant  Thornton  indicated  that  they  considered  these
deficiencies  to be a material  weakness as that term is defined under standards
established  by the  American  Institute  of  Certified  Public  Accountants.  A
material  weakness is a  significant  deficiency  in one or more of the internal
control components that alone or in the aggregate precludes our internal control
from reducing to an appropriately low level the risk that material misstatements
in our financial statements will not be prevented or detected on a timely basis.
The Company  considered these matters in connection with the quarter end closing
of accounts and preparation of related quarterly financial  statements at and as
of March 31, 2004 and determined that no prior period financial  statements were
materially affected by such matters.

In response to the observations made by Grant Thornton, the Company will proceed
more  expeditiously  with its existing  plan to enhance the  Company's  internal
controls and procedures,  which it believes addresses each of the matters raised
by Grant Thornton.

         Changes in Internal Controls

We enhanced our internal control  procedures in March 2004 by adding a full-time
dedicated  accountant with more than seven years work experience to the staff in
our principal  executive  offices in New York, New York.  Our  accountant  works
directly for our outsourced  accounting firm which assists us in the preparation
and  finalization  of our  accounts on an ongoing  basis.  Her  responsibilities
include  preparation  of the Company's  financial  statements on a quarterly and
annual basis and preparation of budget-to-actual  analyses on a quarterly basis.
Our management intends to expand her  responsibilities  on our behalf to include
preparation   of  monthly   financial   statements   and   monthly   and  annual
budget-to-actual  analyses.  We believe the addition of this dedicated  resource
will further enhance the Company's internal control over financial  reporting in
the near term, which management will continue to monitor on a regular basis.

In June 2004, we hired a new employee to serve as our Vice President,  Corporate
Compliance and Associate  General  Counsel.  This new employee has five years of
corporate law experience with a full-service  internationally  based law firm in


                                      -15-



the office  located in New York, New York.  She has  represented  several public
companies and is  knowledgeable  with respect to contract law, the  requirements
under the Sarbanes-Oxley Act and other areas of public disclosure.  We intend to
continue to streamline the  responsibilities  of our Chief Financial Officer and
General  Counsel to permit him to focus more of his time and effort,  as needed,
on the accounting and financial reporting needs of the Company.

Further,  in July 2004,  the Company  adopted,  and  management  implemented,  a
comprehensive set if internal  accounting  controls,  which were approved by the
audit committee.


                       BIOENVISION, INC. AND SUBSIDIARIES

                           PART II - OTHER INFORMATION

Item 1. Legal Proceedings

On April 1, 2003, RLB Capital, Inc. filed a complaint against the Company in the
Supreme Court of the State of New York (Index No. 601058/03). The Complaint
alleged a breach of contract by the Company and demanded judgment against the
Company for $112,500 and warrants to acquire 75,000 shares of the Company's
common stock. The Company submitted its Verified Answer on June 25, 2003 and, in
pertinent part, denied RLB's allegations and asserted counterclaims based on
negligence. In September 2003, the Company filed a motion for summary judgment
and RLB filed its response on October 27, 2003. In December 2003, the Supreme
Court granted the motion for summary judgment and the complaint was dismissed.
In March 2004, the complaint and two counterclaims asserted by the Company were
dismissed with prejudice.

On December 19, 2003, the Company filed a complaint against Dr. Deidre Tessman
and Tessman Technology Ltd. (the "Tessman Defendants") in the Supreme Court of
the State of New York, County of New York (Index No. 03-603984). An amended
complaint alleges, among other things, breach of contract and negligence by
Tessman and Tessman Technology and demands judgment against Tessman and Tessman
Technology in an amount to be determined by the Court. The Tessman Defendants
removed the case to federal court, then remanded it to state court and served an
answer with several purported counterclaims. The Company denies the allegations
in the counterclaims and intends to pursue its claims against the Tessman
Defendants vigorously.

Item 2. Changes in securities and Use of Proceeds

None

Item 3. Defaults upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

None

Item 5. Other information

There is no other information to report that is material to the Company's
financial condition not previously reported.

Item 6. Exhibits and Reports on Form 8-K

A) Exhibits

   31.1 Certification of Christopher B. Wood, Chief Executive Officer, as
        adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

   31.2 Certification of David P. Luci, Chief Financial Officer, as adopted
        pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

   32.1 Certification of Christopher B. Wood , Chief Executive Officer
        pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
        of the Sarbanes-Oxley Act of 2002.


                                      -16-



   32.2 Certification of David P. Luci, Chief Financial Officer, pursuant to
        18 U.S.C. Section 1350, as adopted pursuant Section 906 of the
        Sarbanes-Oxley Act of 2002.

(B) Reports on Form 8-K:

None.


                                      -17-



                                   SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.


Date:  November 15, 2004      By:  /s/ Christopher B. Wood M.D.
                                   ----------------------------
                                   Christopher B. Wood M.D.
                                   Chairman and Chief Executive Officer
                                   (Principal Executive Officer)


Date:  November 15, 2004     By:  /s/ David P. Luci
                                   ----------------
                                  David P. Luci
                                  Chief Financial Officer and General Counsel
                                  (Principal Financial and Accounting Officer)





                                  EXHIBIT INDEX
Exhibit No.


31.1 Certification of Christopher B. Wood, Chief Executive Officer, as adopted
     pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


31.2 Certification of David P. Luci, Chief Financial Officer, as adopted
     pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


32.1 Certification of Christopher B. Wood , Chief Executive Officer pursuant to
     18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
     Sarbanes-Oxley Act of 2002.


32.2 Certification of David P. Luci, Chief Financial Officer, pursuant to 18
     U.S.C. Section 1350, as adopted pursuant to Section 906 of the
     Sarbanes-Oxley Act of 2002.